



National Recommendations and Indicators on Healthcare Associated Infections and Antimicrobial Resistance

Questionnaire for National Contact Points

Version 4, June 2006

This questionnaire is addressed to all European Union Member States (via the official IPSE project National Contact Points) and to all other Member States in the WHO European Region. It should be completed by the National Contact Point in collaboration with those in charge of the national Infection Control programme.

COUNTRY

Country

National Contact Point

DETAILS OF PERSON COMPLETING THE QUESTIONNAIRE

First name

Last name

Title/Position

Institution

Professional address

Phone

Fax

E-mail

Date of Completion

__ / __ / ____ (must be completed by Friday 21 July 2006)

PLEASE RETURN THE COMPLETED QUESTIONNAIRE BY POST OR FAX TO :

IPSE Coordination Office

Université Claude Bernard Lyon1, Laboratoire d'épidémiologie et santé publique

8 avenue Rockefeller – F-69373 LYON Cedex 08

Fax : + 33 4 78 00 93 86



The objective of this questionnaire is to assess the indicators that are used by European countries for monitoring;

- the occurrence of Healthcare Associated Infections (HAI) and Antimicrobial Resistance (AMR).
- the control capabilities developed through their national programme.

If any questions are not applicable or do not relate well to the prevailing situation in your country, please use the **Additional Comments** sections to provide any supplementary information you consider necessary. Thank you for taking part in this important survey.

This questionnaire is divided into the following sections:

Organisation
Surveillance and Reporting
Morbidity Data
Laboratory
Education and Training
Economic Impact

IPSE

**FOR ADDITIONNAL INFORMATION OR ADVICE ABOUT THE COMPLETION OF THE QUESTIONNAIRE,
PLEASE CONTACT:**

Bernardus GANTER BGA@euro.who.int



GLOSSARY OF TERMS

Antimicrobial Resistance (AMR)

For the purposes of this document, only multidrug-resistant bacteria will be considered. In general, this refers to bacteria (excluding *M. tuberculosis*) that are resistant to one or more classes of antimicrobial agents and usually are resistant to all but one or two commercially available antimicrobial agents (e.g. methicillin-resistant *Staphylococcus aureus* – MRSA, vancomycin-resistant *Enterococci* – VRE, extended spectrum beta-lactamase [ESBL]-producing or intrinsically resistant gram-negative bacilli). Multi-drug resistant tuberculosis – MDR-TB refers to *M. tuberculosis* bacilli resistant to any combination of anti-TB drugs that includes isoniazid and rifampicin (the two most effective anti-TB drugs).

Healthcare Associated Infection (HAI)

An infection that develops in a patient who is cared for in any setting where health care is delivered (e.g., acute care hospital, chronic care facility, ambulatory clinic, dialysis centre, home) and is related to receiving health care (i.e. was not incubating or present at the time health care was provided). In ambulatory and home settings, HAI would apply to any infection that is associated with a medical or surgical intervention.

Hospital: For the purposes of this questionnaire, a hospital is defined as an inpatient facility providing acute care.

Surveillance System: A Surveillance System may include one or several schemes for systematic collection, analysis, feedback and use of epidemiological information on Healthcare Associated Infections or Antimicrobial Resistance for prevention and evaluation of control measures.

Composite Indicators: A composite indicator is the formation of individual indicators into a single index, on the basis of an underlying model of the subject being measured. . The individual indicators are selected, combined and weighted in a manner that reflects the subject being measured.

National means that a single programme is implemented throughout the country.



ORGANISATION

1. Describe the **national Healthcare Associated Infection (HAI) and Antimicrobial Resistance (AMR) programmes** which exist in your country.

	HAI	AMR
1.a Does a national programme exist?	Yes <input type="radio"/> No <input type="radio"/>	Yes <input type="radio"/> No <input type="radio"/>
1.b Year of beginning		

2. If a national programme does not exist, but **programmes which do not cover the entire country (regional or provincial) have been implemented**, please describe:

	HAI	AMR
2.a Does a regional/provincial programme exist?	Yes <input type="radio"/> No <input type="radio"/>	Yes <input type="radio"/> No <input type="radio"/>
2.b Geographical area covered (specify)	_____ _____ _____ _____ _____	_____ _____ _____ _____ _____

3. Describe the governmental situation of HAI and AMR in your country.

	HAI	AMR
3.a Are there existing or proposed specific laws on prevention and control of HAI and AMR?	Yes <input type="radio"/> No <input type="radio"/>	Yes <input type="radio"/> No <input type="radio"/>
3.b Is reduction of HAI and AMR included in the government's health objectives of the country?	Yes <input type="radio"/> No <input type="radio"/>	Yes <input type="radio"/> No <input type="radio"/>

Additional comments



ORGANISATION (CONT.)

☞ *If your country has a national HAI and/or AMR programme, please complete the questions below. If your country has HAI and/or AMR programmes not covering the entire country (regional or provincial), please copy pages 5 to 11 and complete as necessary.*

5. Describe the country/region/province concerned.

<p>5.a What is the name of the country/region/province to which the following pages 5 to 11 refer?</p> <p>5.b How many hospitals exist in the country/region/province?</p>	<p>-----</p> <p style="text-align: center;"> _ _ _ _ </p>
--	---

6. Describe the functions performed by any advisory Infection Control committee in relation to the programme. If more than one body is involved, describe their organisation in **Additional Comments**.

<p>6.a Is there an Infection Control committee in charge of running the programme?</p> <p>If yes, what are the main responsibilities of the Infection Control committee?</p>	<p>Yes <input type="radio"/> No <input type="radio"/></p>
<p>6.b Setting up objectives.</p>	<p>Yes <input type="radio"/> No <input type="radio"/></p>
<p>6.c Planning actions.</p>	<p>Yes <input type="radio"/> No <input type="radio"/></p>
<p>6.d Preparing recommendations and guidelines.</p>	<p>Yes <input type="radio"/> No <input type="radio"/></p>
<p>6.e Monitoring indicators.</p>	<p>Yes <input type="radio"/> No <input type="radio"/></p>
<p>6.f Organising training and human resource development.</p>	<p>Yes <input type="radio"/> No <input type="radio"/></p>
<p>6.g Organising surveillance and early warning.</p>	<p>Yes <input type="radio"/> No <input type="radio"/></p>
<p>6.h Evaluating the impact of the programme.</p>	<p>Yes <input type="radio"/> No <input type="radio"/></p>
<p>6.i Evaluating healthcare facilities.</p>	<p>Yes <input type="radio"/> No <input type="radio"/></p>
<p>6.j Other responsibilities – please specify.</p>	<p>-----</p> <p>-----</p> <p>-----</p>
<p>6.k If yes, how often does the Infection Control committee meet?</p>	<p> _ _ times per year</p>
<p>6.l If yes, does the Infection Control committee produce an annual report?</p>	<p>Yes <input type="radio"/> No <input type="radio"/></p>
<p>6.m If yes, how regularly are Infection Control plans prepared?</p>	<p>annual biennial 3-5 yrs >5 yrs</p> <p><input type="radio"/> <input type="radio"/> <input type="radio"/> <input type="radio"/></p>



ORGANISATION (CONT.)

Additional comments

7. Describe recommendations and guidelines provided by the programme. If more than one body is involved, please give details in **Additional Comments**.

What subjects are covered by the programme recommendations and guidelines?		
7.a Surveillance and reporting of HAI	Yes <input type="radio"/>	No <input type="radio"/>
7.b Surveillance and reporting of AMR	Yes <input type="radio"/>	No <input type="radio"/>
7.c Standard precautions	Yes <input type="radio"/>	No <input type="radio"/>
7.d Transmission-base precautions	Yes <input type="radio"/>	No <input type="radio"/>
7.e Prevention of device-related infections- Intravascular catheter	Yes <input type="radio"/>	No <input type="radio"/>
7.f Prevention of device-related infections– Urinary catheter	Yes <input type="radio"/>	No <input type="radio"/>
7.g Prevention of device-related infections– Respiratory ventilation	Yes <input type="radio"/>	No <input type="radio"/>
7.h Rational use of antimicrobials	Yes <input type="radio"/>	No <input type="radio"/>
7.i Staff occupational health	Yes <input type="radio"/>	No <input type="radio"/>
7.j Cleaning, disinfection and sterilisation	Yes <input type="radio"/>	No <input type="radio"/>
7.k Engineering and architectural aspects of healthcare facilities	Yes <input type="radio"/>	No <input type="radio"/>
7.l Other subjects – please specify.		
7.m Are these recommendations or guidelines used for official evaluation (such as authorisation, certification or accreditation)?	Yes <input type="radio"/>	No <input type="radio"/>

Additional comments



ORGANISATION (CONT.)

8. Describe HAI and AMR prevention and control indicators in your country/region/province.

8.a Are indicators defined to assess the preparedness of healthcare facilities to control HAI and AMR?	Yes <input type="radio"/>	No <input type="radio"/>
If yes, which indicators are defined?		
8.b Composite indicators on local Infection Control activities	Yes <input type="radio"/>	No <input type="radio"/>
8.c Composite indicators on local policy to control AMR	Yes <input type="radio"/>	No <input type="radio"/>
8.d HAI rate(s)	Yes <input type="radio"/>	No <input type="radio"/>
8.e AMR rate(s)	Yes <input type="radio"/>	No <input type="radio"/>
8.f Indicators on hand hygiene	Yes <input type="radio"/>	No <input type="radio"/>
8.g Indicators on standard precautions	Yes <input type="radio"/>	No <input type="radio"/>
8.h Indicators on human resources devoted to HAI & AMR control	Yes <input type="radio"/>	No <input type="radio"/>
8.i Other indicators – please specify.	<hr style="border-top: 1px dashed black;"/> <hr style="border-top: 1px dashed black;"/> <hr style="border-top: 1px dashed black;"/> <hr style="border-top: 1px dashed black;"/>	
8.j Is the analysis of the indicator(s) available at national/regional/provincial level?	Yes <input type="radio"/>	No <input type="radio"/>
8.k Is the analysis of the indicator(s) available at healthcare facility level?	Yes <input type="radio"/>	No <input type="radio"/>
8.l Are the indicator(s) which are available at healthcare facility level disclosed to the public?	Yes <input type="radio"/>	No <input type="radio"/>

Additional comments



MORBIDITY DATA

☞ In question 9, if the programme includes a Surveillance System, please answer questions 10, 11 & 12, otherwise proceed to question 13.

10. Describe morbidity data produced by the Surveillance System.

10.a Does the Surveillance System produce incidence rates of HAI?	Yes <input type="radio"/>	No <input type="radio"/>
If the Surveillance System does produce incidence rates of HAI, for which infection sites are rates produced?		
10.b Surgical site infection	Yes <input type="radio"/>	No <input type="radio"/>
10.c Blood-borne infection (bacteraemia)	Yes <input type="radio"/>	No <input type="radio"/>
10.d Pneumonia	Yes <input type="radio"/>	No <input type="radio"/>
10.e Urinary tract infection	Yes <input type="radio"/>	No <input type="radio"/>
10.f Vascular catheter-associated infection	Yes <input type="radio"/>	No <input type="radio"/>
10.g Other infection sites – please specify.	----- ----- -----	
If the Surveillance System does produce incidence rates of HAI, what wards are targeted?		
10.h All types of ward (hospital wide surveillance)	Yes <input type="radio"/>	
10.i Surgical wards	Yes <input type="radio"/>	
10.j ICU wards	Yes <input type="radio"/>	
10.k Obstetrical wards	Yes <input type="radio"/>	
10.l Other wards – please specify.	----- ----- -----	
If the Surveillance System does produce incidence rates of HAI, are the methods used compatible with HELICS European protocols?		
10.m HELICS SSI protocol	Yes <input type="radio"/>	
10.n HELICS ICU protocol level 1	Yes <input type="radio"/>	
10.o HELICS ICU protocol level 2	Yes <input type="radio"/>	
10.p Does the Surveillance System produce prevalence rates of HAI?	Yes <input type="radio"/>	
10.q If yes, are the rates produced periodically?	Yes <input type="radio"/>	
10.r If yes, what is the periodicity?	Every [] [] [] [] months	

Additional comments



MORBIDITY DATA (CONT.)

11. Describe the monitoring of multi-resistant organisms.

11.a Does the Surveillance System monitor multi-resistant organisms?	Yes <input type="radio"/>	No <input type="radio"/>
If yes, what multi-resistant organisms are under surveillance?		
11.b methicillin-resistant <i>Staphylococcus aureus</i> - MRSA	Yes <input type="radio"/>	No <input type="radio"/>
11.c vancomycin-resistant <i>Enterococci</i> - VRE	Yes <input type="radio"/>	No <input type="radio"/>
11.d glycopeptide-intermediate <i>Staphylococcus aureus</i> - GISA	Yes <input type="radio"/>	No <input type="radio"/>
11.e <i>Pseudomonas</i> spp	Yes <input type="radio"/>	No <input type="radio"/>
11.f <i>Acinetobacter</i> spp	Yes <input type="radio"/>	No <input type="radio"/>
11.g multi-drug resistant tuberculosis – MDR-TB	Yes <input type="radio"/>	No <input type="radio"/>
11.h extended spectrum beta-lactamase-producing – ESBL - Enterobacteriaceae	Yes <input type="radio"/>	No <input type="radio"/>
11.i Other multi-resistant organisms – please specify.	----- ----- -----	

12. Describe the collection of information on unusual or threatening HAI (alert and early warning process).

12.a Does the Surveillance System collect information on unusual or threatening HAI (alert and early warning process)?	Yes <input type="radio"/>	No <input type="radio"/>
If yes, for what subjects is information collected?		
12.b Epidemics	Yes <input type="radio"/>	No <input type="radio"/>
12.c Unusual pathogens	Yes <input type="radio"/>	No <input type="radio"/>
12.d Unusual sites	Yes <input type="radio"/>	No <input type="radio"/>
12.e Lethal or severe infection	Yes <input type="radio"/>	No <input type="radio"/>
12.f Infection caused by a contaminated device or product	Yes <input type="radio"/>	No <input type="radio"/>
12.i Other unusual or threatening infections – please specify.	----- ----- -----	
12.f If the Surveillance System does not collect information on unusual or threatening HAI, are there plans to develop such a system in the future?	Yes <input type="radio"/>	No <input type="radio"/>

Additional comments



LABORATORY

13. Describe susceptibility testing for antibiotic-treated organisms in laboratories.

13.a Is it known how many hospital laboratories perform susceptibility testing for antibiotic-treated organisms?	Yes <input type="radio"/>	No <input type="radio"/>			
13.b If yes, what is the percentage performing susceptibility testing?	< 30% <input type="radio"/>	30-50% <input type="radio"/>	50-70% <input type="radio"/>	70-90% <input type="radio"/>	> 90% <input type="radio"/>

EDUCATION & TRAINING

14. Describe training given to healthcare professionals.

14.a Does the programme provide training for healthcare professionals on prevention and control of HAI?	Yes <input type="radio"/>	No <input type="radio"/>
14.b Does the programme provide training for healthcare professionals on prevention and control of AMR?	Yes <input type="radio"/>	No <input type="radio"/>

ECONOMIC IMPACT

15. Describe the cost of HAI to the nation/region/province.

15.a Does the programme estimate the costs of HAI to the national/regional/provincial health system?	Yes <input type="radio"/>	No <input type="radio"/>
15.b If yes, what is the estimated cost of HAI to the national/ regional/provincial health system (amount in euros or converted to euros)?	----- ----- -----	



Additional comments

A series of horizontal dashed lines for writing additional comments. A large, semi-transparent yellow watermark with the text "IPSE" is oriented diagonally across the center of the page.